Albireo Stock Financials


USD 22.11  0.10  0.45%   

Albireo Pharma Revenue Per Employee is quite stable at the moment as compared to the past year. The company's current value of Revenue Per Employee is estimated at 335,837. Average Assets is expected to rise to about 288 M this year, although the value of Net Income Per Employee will most likely fall to (282.4 K).
With this module, you can analyze Albireo financials for your investing period. You should be able to track the changes in Albireo Pharma individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Albireo Most Recent Estimates

EPS Estimate Next Quarter
Diluted Eps
EPS Estimate Current Year
EPS Estimate Next Year
EPS Estimate Current Quarter
Earnings Share
Understanding current and past Albireo Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Albireo Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Albireo Pharma's assets may result in an increase in income on the income statement.


43.78 Million

The financial analysis of Albireo Pharma is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Albireo Pharma includes many different criteria found on its balance sheet. For example, investors should never minimize Albireo Pharma's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Albireo Pharma's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Albireo Pharma.

Albireo Pharma Cash

Chance Of Financial Distress
Over 84
Albireo Pharma has more than 84 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Albireo Pharma stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Albireo Pharma's official financial statements usually reflect Albireo Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Albireo Pharma. For example, before you start analyzing numbers published by Albireo accountants, it's critical to develop an understanding of what Albireo Pharma's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Albireo Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Albireo Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Albireo Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Albireo Pharma. Please utilize our Beneish M Score to check the likelihood of Albireo Pharma's management to manipulate its earnings.

Albireo Pharma Company Summary

Albireo Pharma competes with Regeneron Pharmaceuticals, and Vertex Pharmaceutic. Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. Albireo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 130 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001322505
RegionNorth America
Business Address53 State Street,
Phone857 254 5555
CurrencyUSD - US Dollar
You should never invest in Albireo Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Albireo Stock, because this is throwing your money away. Analyzing the key information contained in Albireo Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Albireo Pharma Key Financial Ratios

Generally speaking, Albireo Pharma's financial ratios allow both analysts and investors to convert raw data from Albireo Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Albireo Pharma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Albireo Pharma reports annually and quarterly.

Albireo Pharma Key Balance Sheet Accounts

201720182019202020212022 (projected)
Accounts Payable1.35 M4.35 M4.79 M5.28 M6.52 M7.03 M
Total Assets73.22 M185.47 M165.07 M285.61 M302.05 M325.9 M
Current Assets55.01 M167.65 M141.8 M261.87 M268.93 M290.16 M
Assets Non Current18.21 M17.82 M23.27 M23.74 M33.12 M35.74 M
Cash and Equivalents53.23 M163.88 M131.84 M251.27 M248.11 M267.69 M
Shareholders Equity65.25 M122.64 M93.16 M181.23 M175.61 M189.47 M
Total Liabilities7.97 M62.83 M71.91 M104.38 M126.44 M136.43 M
Current Liabilities7.93 M12.82 M18.92 M25.28 M45.35 M48.93 M

Albireo Pharma Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Albireo Pharma's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Consolidated Income(24.41 M)(46.11 M)(62.72 M)(107.63 M)(34.03 M)(36.72 M)
Gross Profit1,00012.74 M9.64 M8.31 M39.22 M42.32 M
Interest Expense(40 K)4.84 M5.3 M11.36 M13.93 M15.03 M
Net Income(24.41 M)(46.11 M)(62.72 M)(107.63 M)(34.03 M)(36.72 M)
Operating Expenses24.58 M50.63 M70.75 M104.58 M162.71 M175.55 M
Operating Income(24.58 M)(37.89 M)(61.11 M)(96.27 M)(123.48 M)(133.23 M)
Revenues1,00012.74 M9.64 M8.31 M40.58 M43.78 M

Albireo Pharma Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Albireo Pharma. It measures of how well Albireo is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Albireo Pharma brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Albireo had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Albireo Pharma has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure4.31 M(47 K)(540 K)(78 K)(465 K)(477.24 K)
Depreciation Amortization and Accretion35 K45 K127 K192 K274 K282.35 K
Net Cash Flow or Change in Cash and Cash Equivalents23.3 M110.65 M(32.04 M)119.43 M(3.17 M)(3.25 M)
Issuance Purchase of Equity Shares48.51 M94.66 M23.5 M196.04 M2.76 M2.83 M
Net Cash Flow from Financing45.84 M139.18 M23.5 M220.28 M2.76 M2.83 M
Net Cash Flow from Investing4.31 M(47 K)(540 K)(78 K)102.92 M111.05 M
Net Cash Flow from Operations(27.57 M)(26.8 M)(52.92 M)(101.03 M)(107.56 M)(110.39 M)
Effect of Exchange Rate Changes on Cash718 K(1.68 M)(2.09 M)260 K(1.29 M)(1.32 M)
Share Based Compensation3.7 M5.55 M7.58 M14.62 M15.93 M17.19 M

Albireo Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Albireo Pharma's current stock value. Our valuation model uses many indicators to compare Albireo Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Albireo Pharma competition to find correlations between indicators driving Albireo Pharma's intrinsic value. More Info.
Albireo Pharma is rated third in price to earning category among related companies. It is rated third in return on asset category among related companies . Average Assets is expected to rise to about 288 M this year. Tangible Asset Value is expected to rise to about 307.3 M this year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Albireo Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Albireo Pharma's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Albireo Pharma's earnings, one of the primary drivers of an investment's value.

Albireo Pharma Systematic Risk

Albireo Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Albireo Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Albireo Pharma correlated with the market. If Beta is less than 0 Albireo Pharma generally moves in the opposite direction as compared to the market. If Albireo Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Albireo Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Albireo Pharma is generally in the same direction as the market. If Beta > 1 Albireo Pharma moves generally in the same direction as, but more than the movement of the benchmark.

About Albireo Pharma Financials

What exactly are Albireo Pharma Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Albireo Pharma's income statement, its balance sheet, and the statement of cash flows. Potential Albireo Pharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Albireo Pharma investors may use each financial statement separately, they are all related. The changes in Albireo Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Albireo Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Albireo Pharma is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Albireo has grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Albireo Pharma November 27, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Albireo Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Albireo Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Albireo Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Albireo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Albireo Pharma's daily price indicators and compare them against related drivers.
Downside Deviation3.83
Information Ratio0.0576
Maximum Drawdown29.76
Value At Risk(5.06)
Potential Upside10.04
Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for Albireo Stock analysis

When running Albireo Pharma price analysis, check to measure Albireo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Albireo Pharma is operating at the current time. Most of Albireo Pharma's value examination focuses on studying past and present price action to predict the probability of Albireo Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Albireo Pharma's price. Additionally, you may evaluate how the addition of Albireo Pharma to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Is Albireo Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Albireo Pharma. If investors know Albireo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Albireo Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
455.6 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Albireo Pharma is measured differently than its book value, which is the value of Albireo that is recorded on the company's balance sheet. Investors also form their own opinion of Albireo Pharma's value that differs from its market value or its book value, called intrinsic value, which is Albireo Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Albireo Pharma's market value can be influenced by many factors that don't directly affect Albireo Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Albireo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Albireo Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Albireo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.